Therapy helps control excessive red blood cell production. The U.S. Food and Drug Administration (FDA) has approved rusfertide (Mimrylo) for adult patients with polycythemia vera, a rare, slow-growing blood cancer that causes excessive blood...
The FDA approves a RAS-targeted therapy, and government-funded research explores topics often neglected by industry trials.
Daraxonrasib is approved for previously treated or systemic-therapy-ineligible metastatic pancreatic adenocarcinoma. The U.S. Food and Drug Administration (FDA) has approved daraxonrasib (Rasonque) for adults with metastatic pancreatic adenocarcinoma whose cancer has progressed following at...
Two zanidatamab-based regimens were approved for certain HER2-positive advanced gastric, gastroesophageal junction, or esophageal cancers. The U.S. Food and Drug Administration (FDA) has approved zanidatamab-hrii (Ziihera) as part of two first-line treatment regimens for...
Featuring insights from Carl H. June, MD, FAACR, this post covers the ongoing challenges facing CAR T-cell therapy and some of the latest approaches that strive to overcome these hurdles. Learn about recent efforts...
The August 2026 Editors’ Picks from AACR journals cover the impact of weight loss and omega-3 supplementation on breast cancer risk, early-onset cancer prediction, and more.
An mRNA vaccine with immunotherapy may lower recurrence in melanoma, and active surveillance for prostate cancer has increased in the Veterans Affairs health system over the last two decades.
Ovarian cancer is often diagnosed at an advanced stage, but research is reshaping how scientists understand and treat the disease. From discoveries about its origins to new FDA-approved therapies, learn how scientific advances are...
Patients are waiting longer to start treatment than they did a decade ago, and an experimental pancreatic cancer drug is reaching patients ahead of FDA approval.
Antibody-drug conjugates, or ADCs, have emerged as a significant class of cancer therapies over the past two decades. New research has helped to revolutionize the drug class and deliver next-generation designs and approaches.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More